Short Interest in Anbio Biotechnology (NASDAQ:NNNN) Increases By 50.5%

Anbio Biotechnology (NASDAQ:NNNN) was the target of a significant increase in short interest during the month of July. As of July 31st, there was short interest totaling 47,525 shares, an increase of 50.5% from the July 15th total of 31,583 shares. Based on an average trading volume of 38,778 shares, the days-to-cover ratio is presently 1.2 days. Currently, 0.0% of the company’s stock are sold short.

Wall Street Analyst Weigh In

Separately, Weiss Ratings downgraded Anbio Biotechnology from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, July 29th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Anbio Biotechnology Trading Down 5.4%

NASDAQ NNNN traded down $0.45 on Wednesday, hitting $7.90. 34,989 shares of the stock traded hands, compared to its average volume of 52,953. The stock has a 50-day moving average of $11.91 and a 200 day moving average of $20.97. Anbio Biotechnology has a twelve month low of $7.08 and a twelve month high of $54.50.

Anbio Biotechnology Company Profile

Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs.